HOTH Share Price Performance
US$0
-0.87 (-100.00%)
Price US$0
Fair ValueUS$5.30
Share Pricen/a
Hoth Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 2 Comments on narratives written by author
- 153 Fair Values set on narratives written by author
HOTH Community Narratives
JO
Fair Value US$5.3 77.7% undervalued intrinsic discount
100% Patient Improvement in trial puts this $16M Biotech on the radar
19users have liked this narrative
2users have commented on this narrative
134users have followed this narrative
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.Read more
19users have liked this narrative
2users have commented on this narrative
134users have followed this narrative
JO
US$5.3
77.7% undervalued intrinsic discount
Jolt_Communications Fair Value
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0
Snowflake Analysis
Hoth Therapeutics, Inc. Key Details
About HOTH
- Founded
- 2017
- Employees
- 3
- CEO
- WebsiteView website
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
